Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (NASDAQ: SRPT) and FibroGen (NASDAQ: FGEN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPTResearch Report) and FibroGen (FGENResearch Report).

Sarepta Therapeutics (SRPT)

In a report issued on July 1, Tim Lugo from William Blair maintained a Buy rating on Sarepta Therapeutics. The company’s shares opened today at $150.58.

Lugo commented:

“We attended the Orlando, Florida. The conference brought together patients, caregivers, researchers, and industry representatives to discuss current treatment and future therapeutic development for Duchenne muscular dystrophy (DMD). We include our highlights below . As we have previously discussed, Pfizer’s (PFE $ 43.32) gene therapy does not look to be competitive with immunogenicity issues and moderate efficacy: Pfizer presented the first data from six boys with DMD in its Phase I/II trial of PF-06939926 (AAV9.microdystrophin, see our note: Clear Leader in DMD With No Close No. 2 After Pfizer Results Disappoint).”

According to TipRanks.com, Lugo is a 4-star analyst with an average return of 7.2% and a 43.5% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, BioMarin Pharmaceutical Inc., and Aclaris Therapeutics Inc.

Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $204.75, which is a 36.0% upside from current levels. In a report issued on June 17, H.C. Wainwright also assigned a Buy rating to the stock with a $267 price target.

See today’s analyst top recommended stocks >>

FibroGen (FGEN)

In a report issued on July 2, Andy Hsieh from William Blair reiterated a Hold rating on FibroGen. The company’s shares opened today at $44.28.

Hsieh observed:

“We take a deeper look into the Phase II results in this note.”

According to TipRanks.com, Hsieh is a 2-star analyst with an average return of 1.1% and a 50.0% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Viking Therapeutics, and Seattle Genetics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for FibroGen with a $50 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.